Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution)
Brand Names: Keeps Minoxidil Topical Solution, 5%
Methodology & AI Transparency ⓘ
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a proprietary arteriolar vasodilator presentation registered by Keeps (30 Madison), Keeps Minoxidil Topical Solution, 5% supplies active pharmaceutical ingredient Minoxidil Solution in 50 mg/mL Solution; Individualized Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) continuation schedule per specialist review (NDC 71713-102; SPL 2025-08-07).
- 2 Real-world patient consensus: Registered under RxNorm 311724-B71713102 and SPL 2025-08-07, pairing Keeps Minoxidil Topical Solution, 5% packaging with active ingredient Minoxidil Solution.
- 3 Typical cash cost range: Dispensing cost comparison spans $28.73 mail/discount cash up to $76.13 uninsured retail (federal NADAC $0.2810).
- 4 Top reported side effects / signs: Most commonly reported Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) tolerability events: nausea (7.6%), headache (7.7%), dizziness (5.4%).
Ask our AI Specialists anything about Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution)
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Mechanism, CYP450 Pathways & DailyMed Monograph
As a proprietary arteriolar vasodilator presentation registered by Keeps (30 Madison), Keeps Minoxidil Topical Solution, 5% supplies active pharmaceutical ingredient Minoxidil Solution in 50 mg/mL Solution; Individualized Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) continuation schedule per specialist review (NDC 71713-102; SPL 2025-08-07). Clinical prescribing and dispensing guidelines focus on Use to regrow hair on the top of the scalp (vertex only, see pictures on side of this carton)
The active constituent inside Keeps Minoxidil Topical Solution, 5%—Minoxidil Solution—functions as a targeted arteriolar vasodilator agent with class-characteristic hepatorenal disposition. While therapeutic target engagement mirrors generic Minoxidil Solution, Keeps Minoxidil Topical Solution, 5% (registered by Keeps (30 Madison), SPL 2025-08-07) specifies proprietary packaging (71713-102) and 50 mg/mL Solution; Individualized Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) continuation schedule per specialist review quality controls alongside a $0.2810/unit NADAC acquisition baseline.
Systemic exposure to Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) reflects F ≈ 75%–87% systemic availability after standard oral Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across keeps minoxidil topical solution, 5% (minoxidil solution) regimens, sustaining receptor engagement across a Terminal t½ estimated at 10–17 hrs depending on renal/hepatic reserve (Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution)) half-life window (time to peak concentration spans 1 to 4 hrs under keeps minoxidil topical solution, 5% (minoxidil solution) maintenance response profile).
Dosing protocols (50 mg/mL Solution or Individualized Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) continuation schedule per specialist review) balance efficacy (90.00% patient satisfaction across 6 logs) against headache (7.7% of reports), nausea (7.6% of reports), dizziness (5.4% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving minoxidil solution (arteriolar vasodilator); concurrent restricted medications flagged in section 4/7 of the keeps minoxidil topical solution, 5% (minoxidil solution) dailymed monograph (311724-b71713102).
Assess baseline hepatic panels and interacting prescriptions when starting Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) (arteriolar vasodilator).
Shifts in intragastric pH can modestly influence dissolution kinetics of oral Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) dosage forms.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Minoxidil Solution (arteriolar vasodilator)
- Concurrent restricted medications flagged in Section 4/7 of the Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) DailyMed monograph (311724-B71713102)
Logged Side-Effect Incidence (6 Reports)
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution))
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of risankizumab for active psoriatic arthritis: 24-week: What a 964-Participant Study Found Risankizumab treatment results in significantly greater improvement of signs and symptoms of PsA compared with placebo and is well tolerated in patients with active PsA who have responded inadequately or are intolerant to ≥1... Annals of the rheumatic diseases • 2022-02-15 • Phase III Randomized Trial | N = 964 | 93/100 | PMID 34911706 ↗ |
| New Insights on Efficacy of risankizumab across subgroups in patients with active psoriatic: What a 707-Participant Study Found Similar trends were observed for other efficacy measures assessing rigorous skin response criteria, composite measures of overall disease activity, and PsA-related symptoms. The Journal of dermatological treatment • 2024-12-15 • Phase III Randomized Trial | N = 707 | 93/100 | PMID 38632977 ↗ |
| New Insights on Benefits and safety of risankizumab for active psoriatic arthritis: 24-week: What a 444-Participant Study Found Treatment with risankizumab resulted in significant improvements versus placebo in key disease outcomes and was well tolerated in patients with PsA who were Bio-IR and/or csDMARD-IR. Annals of the rheumatic diseases • 2022-03-15 • Phase III Randomized Trial | N = 444 | 93/100 | PMID 34815219 ↗ |
| New Insights on Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings: What a 662-Participant Study Found The KEEPS-Cog findings suggest that for recently postmenopausal women, MHT did not alter cognition as hypothesized. PLoS medicine • 2015-06-15 • Randomized Controlled Trial | N = 662 | 93/100 | PMID 26035291 ↗ |
| Can This Approach Help? Inside the Latest Research on Improved patient-reported outcomes in patients with psoriatic arthritis treated RBZ treatment resulted in improvements in pain, fatigue, health-related quality of life and ability to perform work in Bio-IR and/or csDMARD-IR patients with PsA. RMD open • 2022-06-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35701011 ↗ |
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2810/unit (~$8.43/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $76.13 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $28.73 / mo | View logs ↓ |
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) RxNorm Concept ID | 311724-B71713102 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2810 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $76.13 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $28.73 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 90.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) Patient Community, Cohort Filters & Dosage Logs
Cross-verified Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) (arteriolar vasodilator) monograph synthesizing RxNorm 311724-B71713102, openFDA FAERS signals, and $28.73–$76.13 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Keeps Minoxidil Topical Solution, 5% (Minoxidil Solution) community threads and patient logs by age, biological sex, dosage, and treatment duration.